• Stoke Therapeutics, Biogen flagged long-term zorevunersen data for Dravet syndrome, scheduled for presentation at the European Epilepsy Congress.
• Long-running extension studies showed sustained seizure control, with continued gains in cognition, behavior, quality of life over multiple years.
• An exploratory analysis indicated fewer severe seizure types linked to SUDEP risk, supporting a potential disease-modifying profile.
• The pivotal Phase 3 EMPEROR trial finished enrollment for its primary analysis population, with results expected in Q3 2027.
• Stoke plans a rolling FDA NDA in H2 2027 if Phase 3 data support filing; long-term dosing remained generally well tolerated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260903210314) on September 03, 2026, and is solely responsible for the information contained therein.